Table 12:
Total Costs and Net Budget Impact for an Increasing Uptake Rate for SCIG Versus Continued Current Uptake Rate in Ontario, Base Case
| Results ($) | |||||
|---|---|---|---|---|---|
| Year 1 | Year 2 | Year 3 | Year 4 | Year 5 | |
| Total cost of reference scenario: current uptake rate of SCIG (22%) | 21,315,682 | 22,935,829 | 24,776,046 | 26,771,329 | 28,907,221 |
| SCIG (adults and children) | |||||
| Adult patients | 3,950,085 | 4,209,543 | 4,530,610 | 4,905,188 | 5,297,603 |
| Pediatric patients | 326,764 | 339,504 | 371,333 | 392,552 | 424,380 |
| IVIG (adults and children) | |||||
| Adult patients | 15,689,462 | 16,923,912 | 18,297,735 | 19,771,111 | 21,344,039 |
| Pediatric patients | 1,349,371 | 1,462,870 | 1,576,368 | 1,702,478 | 1,841,198 |
| Total cost of new scenario: increased uptake rate of SCIG | 20,882,598 | 22,215,224 | 23,803,490 | 25,504,561 | 27,347,249 |
| SCIG (adults and children) | |||||
| Adult patients | 7,827,691 | 9,685,517 | 11,932,985 | 14,465,846 | 17,087,892 |
| Pediatric patients | 642,635 | 785,104 | 965,465 | 1,177,655 | 1,389,846 |
| IVIG (adults and children) | |||||
| Adult patients | 11,428,618 | 10,811,393 | 10,034,884 | 9,079,181 | 8,163,299 |
| Pediatric patients | 983,654 | 933,210 | 870,155 | 781,879 | 706,213 |
| Net budget impact | –433,083 | –720,606 | –972,557 | –1,266,768 | –1,559,972 |
Abbreviations: IVIG, hospital-based intravenous immunoglobulin; SCIG, home-based subcutaneous immunoglobulin.
Note: Numbers may be inexact due to rounding.